These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 9783801)

  • 1. The MACOP-B and VACOP-B combination chemotherapy for young patients with intermediate-grade non-Hodgkin's lymphoma.
    Dreiher J; Shpilberg O; Raanani P; Chetrit A; Ben-Bassat I
    Leuk Res; 1998 Nov; 22(11):997-1002. PubMed ID: 9783801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study.
    Zinzani PL; Stefoni V; Finolezzi E; Brusamolino E; Cabras MG; Chiappella A; Salvi F; Rossi A; Broccoli A; Martelli M
    Clin Lymphoma Myeloma; 2009 Oct; 9(5):381-5. PubMed ID: 19858058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy with MACOP-B and VACOP-B for intermediate- and high-grade non-Hodgkin's lymphoma: clinical results and analysis of prognostic factors.
    Pichert G; Peters J; Stahel RA; Dommann C; Joss R; Gebbers JO; Kroner T; Sulser H; Honegger HP; Maurer R
    Ann Oncol; 1992 Sep; 3(8):645-9. PubMed ID: 1280460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MACOP-B and VACOP-B in diffuse large cell lymphomas and MOPP/ABV in Hodgkin's disease.
    O'Reilly SE; Hoskins P; Klimo P; Connors JM
    Ann Oncol; 1991 Jan; 2 Suppl 1():17-23. PubMed ID: 1710485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
    Fisher RI; Gaynor ER; Dahlberg S; Oken MM; Grogan TM; Mize EM; Glick JH; Coltman CA; Miller TP
    N Engl J Med; 1993 Apr; 328(14):1002-6. PubMed ID: 7680764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group.
    Sertoli MR; Santini G; Chisesi T; Congiu AM; Rubagotti A; Contu A; Salvagno L; Coser P; Porcellini A; Vespignani M
    J Clin Oncol; 1994 Jul; 12(7):1366-74. PubMed ID: 7517442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intensive weekly combination chemotherapy for patients with intermediate-grade and high-grade non-Hodgkin's lymphoma.
    Sweetenham JW; Mead GM; Whitehouse JM
    J Clin Oncol; 1991 Dec; 9(12):2202-9. PubMed ID: 1720454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MACOP-B vs F-MACHOP regimen in the treatment of high-grade non-Hodgkin's lymphomas.
    Mazza P; Zinzani PL; Martelli M; Fiacchini M; Bocchia M; Pileri S; Falini B; Martelli MF; Amadori S; Papa G
    Leuk Lymphoma; 1995 Feb; 16(5-6):457-63. PubMed ID: 7540460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Long-term results with MACOP-B and radiation therapy for aggressive lymphomas].
    Krieger G; Kreysing E; Kneba M
    Onkologie; 2001 Feb; 24 Suppl 1():49-58. PubMed ID: 11441311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MACOP-B chemotherapy for the treatment of high grade and intermediate grade non Hodgkin's lymphoma.
    Oster W; Forsthuber T; Hennekeuser HH; Gamm H; Lindemann A; Schmitz G; Fuhr HG; Hinterberger R; Kreiter H; Thoenes W
    Blut; 1990 Jan; 60(1):23-7. PubMed ID: 1688725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gonadal function after MACOP-B or VACOP-B with or without dose intensification and ABMT in young patients with aggressive non-Hodgkin's lymphoma.
    Müller U; Stahel RA
    Ann Oncol; 1993 May; 4(5):399-402. PubMed ID: 7688980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methylenetetrahydrofolate reductase C677T and A1298C gene variants in adult non-Hodgkin's lymphoma patients: association with toxicity and survival.
    Gemmati D; Ongaro A; Tognazzo S; Catozzi L; Federici F; Mauro E; Della Porta M; Campioni D; Bardi A; Gilli G; Pellati A; Caruso A; Scapoli GL; De Mattei M
    Haematologica; 2007 Apr; 92(4):478-85. PubMed ID: 17488658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment results with an aggressive chemotherapeutic regimen (MACOP-B) for intermediate- and some high-grade non-Hodgkin's lymphomas.
    Schneider AM; Straus DJ; Schluger AE; Lowenthal DA; Koziner B; Lee BJ; Wong G; Clarkson BD
    J Clin Oncol; 1990 Jan; 8(1):94-102. PubMed ID: 1688617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B.
    Todeschini G; Secchi S; Morra E; Vitolo U; Orlandi E; Pasini F; Gallo E; Ambrosetti A; Tecchio C; Tarella C; Gabbas A; Gallamini A; Gargantini L; Pizzuti M; Fioritoni G; Gottin L; Rossi G; Lazzarino M; Menestrina F; Paulli M; Palestro M; Cabras MG; Di Vito F; Pizzolo G
    Br J Cancer; 2004 Jan; 90(2):372-6. PubMed ID: 14735179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A third generation regimen VACOP-B with or without adjuvant radiotherapy for aggressive localized non-Hodgkin's lymphoma: report from the Italian Non-Hodgkin's Lymphoma Co-operative Study Group.
    Santini G; De Souza C; Aversa S; Patti C; Tedeschi L; Candela M; Olivieri A; Chisesi T; Rubagotti A; Centurioni R; Nardi V; Congiu M; Gennaro M; Truini M;
    Braz J Med Biol Res; 2004 May; 37(5):719-28. PubMed ID: 15107935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-term weekly chemotherapy followed by high-dose therapy with autologous bone marrow transplantation for lymphoblastic and Burkitt's lymphomas in adult patients.
    Jost LM; Jacky E; Dommann-Scherrer C; Honegger HP; Maurer R; Sauter C; Stahel RA
    Ann Oncol; 1995 May; 6(5):445-51. PubMed ID: 7545428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate- or high-grade non-Hodgkin's lymphoma: results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma Study.
    Fisher RI; Gaynor ER; Dahlberg S; Oken MM; Grogan TM; Mize EM; Glick JH; Coltman CA; Miller TP
    Ann Oncol; 1994; 5 Suppl 2():91-5. PubMed ID: 7515652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advanced diffuse non-Hodgkin's lymphoma. Analysis of prognostic factors by the international index and by lactic dehydrogenase in an intergroup study.
    Gordon LI; Andersen J; Colgan J; Glick J; Resnick GD; O'Connell M; Cassileth PA
    Cancer; 1995 Feb; 75(3):865-73. PubMed ID: 7530168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomized trial.
    Martelli M; Gherlinzoni F; De Renzo A; Zinzani PL; De Vivo A; Cantonetti M; Falini B; Storti S; Meloni G; Rizzo M; Molinari AL; Lauria F; Moretti L; Lauta VM; Mazza P; Guardigni L; Pescarmona E; Pileri SA; Mandelli F; Tura S
    J Clin Oncol; 2003 Apr; 21(7):1255-62. PubMed ID: 12663712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cyclophosphamide, vincristine, prednisone, bleomycin, doxorubicin, and procarbazine (COPBLAM-I) regimen for intermediate-grade non-Hodgkin's lymphoma. Long term follow-up in 51 patients.
    Shpilberg O; Shiff J; Chetrit A; Ramot B; Ben-Bassat I
    Cancer; 1994 Dec; 74(11):3029-33. PubMed ID: 7525042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.